Comparative Effectiveness of Cell‐Based Versus Egg‐Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022–2023 Season Among Adults 18–64 Years
This retrospective cohort study evaluated the comparative vaccine effectiveness (cVE) of licensed standard-dose cell-based versus egg-based influenza vaccines in preventing influenza hospitalization among adults 18-64 years during the 2022-2023 season. The cohort included eligible Kaiser Permanente Southern California members who received ≥ 1 dose of influenza vaccine (n = 848,334). The adjusted cVE against influenza hospitalization was -10.1% (95% CI: -49.8%, 37.8%) in the 18- to 49-year-old cohort. In the 50- to 64-year-old cohort, the adjusted cVE was 14.9% (-33.8%, 52.1%). Cell-based and egg-based influenza vaccines conferred comparable protection against influenza hospitalization in adults 18-64 years of age in the 2022-2023 season.
Authors
- Bradley K. Ackerson (ORCID: https://orcid.org/0000-0002-0816-7345)
- Gina S. Lee (ORCID: https://orcid.org/0000-0002-7554-9116)
- Lina S. Sy (ORCID: https://orcid.org/0000-0003-2762-9266)
- Tianyu Sun (ORCID: https://orcid.org/0000-0002-3996-1381)
- Jennifer H Ku (ORCID: https://orcid.org/0000-0001-9469-5875)
- Lei Qian (ORCID: https://orcid.org/0000-0001-8001-3992)
- Evan J. Anderson (ORCID: https://orcid.org/0000-0002-1576-4420)
- Yi Luo (ORCID: https://orcid.org/0000-0001-8990-2470)
- Emily Rayens (ORCID: https://orcid.org/0000-0003-3369-3475)
- Hung Fu Tseng (ORCID: https://orcid.org/0000-0001-6184-6534)
- Julia E. Tubert (ORCID: https://orcid.org/0000-0003-0779-888X)
- Yoonyoung Park (ORCID: https://orcid.org/0000-0002-5990-1220)
- Punam P. Modha (ORCID: https://orcid.org/0009-0008-2274-1543)
Institutions
- Kaiser Permanente (US)
- Moderna Therapeutics (United States) (US)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1111/irv.70025
- Citations
- 3
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Pfizer
- GlaxoSmithKline
- Kaiser Permanente
- Moderna
- Genentech
- Janssen Pharmaceuticals